$5.96
-0.14(-2.22%)
Mkt Cap $119M
$3.35
$12.09
52-Week Range
At a Glance
AI-generatedNeonc Technologies reported $40.0K revenue against a $58.2M operating loss and $62.1M net loss in FY2025, reflecting heavy clinical-stage investments and Nasdaq-related administrative expansion amid pre-commercial operations.
8-K
NeOnc Technologies Holdings, Inc. reported Q4 and full-year 2025 financial results with a $62.1 million net loss, alongside clinical progress in NEO212 Phase 1 completion and NEO100 Phase 2a full enrollment.$119M
Market Cap
$40.4K
Revenue
-$53M
Net Income
Employees8
Fundamentals
How The Business Makes Money
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001979414
ISINUS64051A1016
CUSIP64051A101
Phone310-663-7831
Address8335 Sunset Boulevard, Calabasas, CA, 90069, US
SEC EDGAR